{
  "id": 9419464,
  "title": "Basecamp Research Raises $140M to Advance AI-Designed Medicines",
  "url": "https://urgent.news/2026/09/23/basecamp-research-raises-140m-to-advance-ai-designed-medicines",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-23T21:20:44.000Z",
  "source": {
    "name": "Ventureburn",
    "slug": "ventureburn",
    "url": "https://ventureburn.com/basecamp-research-raises-140m-ai-medicines/"
  },
  "original_language": "en",
  "account": "Basecamp Research has secured $140 million in Series C funding to propel its AI-designed medicine platform forward. Led by venture capital firm S32, the oversubscribed round attracted investment from prominent technology and healthcare investors, including Anthropic’s Anthology Fund, NVIDIA, Catalio Capital Management, True Ventures, NATO Innovation Fund, Redalpine, Singular and The Rockefeller Foundation.\n\nThe company, founded in 2019 by Glen Gowers and Timothy Hyde, utilizes its Trillion Gene Atlas - the world’s largest proprietary biological AI training dataset - to power its EDEN models. These models train on over 100 billion novel genes amassed through partnerships spanning 30 countries on every continent. The EDEN models aim to uncover genomic patterns and generate potential candidates for next-generation medicines to treat conditions like cancer, autoimmune diseases, and others.\n\nBasecamp’s approach combines frontier AI models with proprietary biological data and DNA-writing technology to design long and complex DNA sequences for therapeutic applications. This could enable more sophisticated and customizable cell therapies, potentially reducing manufacturing requirements for future cell treatments. The company has already demonstrated strong preclinical results across multiple modalities.\n\nBasecamp plans to use the $140 million to advance its pipeline of AI-designed therapeutics towards clinical development. The company will form a six-program pipeline to test the technology across various diseases. It is also seeking to expand pharmaceutical partnerships around its platform. Richard Pearce has been appointed as chief business officer, bringing experience from his previous role at Biogen, while Andy Conrad from Google’s Verily will join Basecamp’s board.",
  "summary": "Basecamp Research Raises $140M for AI-Designed Medicines Basecamp Research has raised $140 million in Series C funding to advance AI-designed medicines. The oversubscribed round was led by S32, with backing The post Basecamp Research Raises $140M to Advance AI-Designed Medicines appeared first on Ventureburn .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}